retatrutide clinical trial results 2024 Eli Lilly infiltrates anti-obesity market as Phase III for begins Tirzepatide shows 47% greater weight
Description
2024;7(11):e2447644
results are not guaranteed
0.83 0.03, n = 3
It is approved for weight management in adults and pediatric patients 12 years and older with obesity, as well as adults with overweight who have at least one weight-related health condition
The fraction of weight lost as fat-free mass depends on baseline adiposity, age, sex, diet, protein intake, inactivity, resistance training, metabolic state, and the rate and duration of weight loss
T., Correll, C
00967-0/asset/e600c3fc-c7b2-4bc5-adb8-0138decc3ad3/main.assets/gr3_lrg.jpg)
